PMID- 15812261
OWN - NLM
STAT- MEDLINE
DCOM- 20050802
LR  - 20191026
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 20
IP  - 3
DP  - 2005 May
TI  - Efficacy and safety of direct transition to risperidone long-acting injectable in 
      patients treated with various antipsychotic therapies.
PG  - 121-30
AB  - The maintained antipsychotic efficacy of risperidone long-acting injectable 
      (RLAI) was investigated in patients with schizophrenia or other psychoses who 
      were transitioned directly from their previous antipsychotic medication. Patients 
      symptomatically stable, but considered to require a treatment change, received 25 
      mg of RLAI (increased to 37.5 or 50 mg, if necessary) every 2 weeks for 6 months. 
      Assessments included Positive and Negative Syndrome Scale (PANSS), Clinical 
      Global Impression-Severity (CGI-S), Global Assessment of Functioning (GAF), SF-36 
      Health-Related Quality of Life Questionnaire and Extrapyramidal Symptoms Rating 
      Scale (ESRS). Of 1876 patients enrolled, 74% completed the 6-month study. The 
      most frequent reasons for treatment change were non-compliance (38%), 
      insufficient efficacy (33%) and side-effects (26%). There was a significant 
      reduction from baseline to endpoint in mean total PANSS score and in the scores 
      on all PANSS subscales and symptom factors (P<0.001). CGI-S improved 
      significantly, as did mean GAF score, all factors on the SF-36 and patient 
      satisfaction with treatment. Scores on ESRS showed significant, sustained 
      improvements throughout the study period. Direct initiation of RLAI was effective 
      and well tolerated. RLAI provides an advancement in the treatment options 
      available for a wide range of patients requiring long-term antipsychotic therapy.
FAU - Moller, Hans-Jurgen
AU  - Moller HJ
AD  - Department of Psychiatry, University of Munich, Germany. 
      hans-juergen.moeller@med.uni-muenchen.de
FAU - Llorca, Pierre-Michel
AU  - Llorca PM
FAU - Sacchetti, Emilio
AU  - Sacchetti E
FAU - Martin, Stephen D
AU  - Martin SD
FAU - Medori, Rossella
AU  - Medori R
FAU - Parellada, Eduard
AU  - Parellada E
CN  - StoRMi Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage/adverse effects/*therapeutic use
MH  - Basal Ganglia Diseases/chemically induced/epidemiology
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Male
MH  - Microspheres
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*drug therapy/psychology
MH  - Quality of Life
MH  - Risperidone/*administration & dosage/adverse effects/*therapeutic use
MH  - Schizophrenia/drug therapy
EDAT- 2005/04/07 09:00
MHDA- 2005/08/03 09:00
CRDT- 2005/04/07 09:00
PHST- 2005/04/07 09:00 [pubmed]
PHST- 2005/08/03 09:00 [medline]
PHST- 2005/04/07 09:00 [entrez]
AID - 00004850-200505000-00001 [pii]
AID - 10.1097/00004850-200505000-00001 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2005 May;20(3):121-30. doi: 
      10.1097/00004850-200505000-00001.